Datroway becomes the first and only therapy to show overall survival benefit versus chemotherapy in this difficult-to-treat patient population
Through this acquisition Merck has added Ohtuvayre (ensifentrine) to its growing cardio-pulmonary pipeline and portfolio
Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies
Investment to expand manufacturing and global medicine supply capacity
The NDA submission follows the successful completion of a pivotal Phase III global clinical trial
Takeda will seek an external partner to leverage its cell therapy platform technologies
Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention
Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio
A Post Graduate in Science faculty and has a wide experience spanning over 35 years in the field of manufacturing Bulk Drugs and Active Pharmaceutical Intermediaries
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
Subscribe To Our Newsletter & Stay Updated
